Direkt zum Inhalt
Merck
  • Verification of cefmetazole and cefpodoxime proxetil contamination to other pharmaceuticals by liquid chromatography-tandem mass spectrometry.

Verification of cefmetazole and cefpodoxime proxetil contamination to other pharmaceuticals by liquid chromatography-tandem mass spectrometry.

Chemical & pharmaceutical bulletin (2006-10-04)
Naoto Fukutsu, Yuich Sakamaki, Takao Kawasaki, Koichi Saito, Hiroyuki Nakazawa
ZUSAMMENFASSUNG

Cross-contamination is a critical issue for pharmaceutical manufacturing, especially for beta-lactam antibiotics. Thus, an analytical method for the simultaneous determination of beta-lactam antibiotics cefmetazole (CMZ) and cefpodoxime proxetil (CPDXPR) contaminants in non-beta-lactam pharmaceuticals was developed using high-performance liquid chromatography-tandem mass spectrometry. The developed method was found to be sensitive at the detection limit of 0.002 ppm for both compounds. Mean recoveries of CMZ and CPDXPR from olmesartan medoxomil (OLM) tablets were 96.7 to 102.2% and 88.9 to 94.2%, respectively. The developed method was successfully applied for the verification of CMZ and CPDXPR contamination to actually manufactured OLM tablets.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

USP
Cefpodoximproxetil, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Cefmetazole sodium salt
Cefpodoximproxetil, European Pharmacopoeia (EP) Reference Standard
Cefpodoximproxetil für die Peakidentifizierung, European Pharmacopoeia (EP) Reference Standard
Cefpodoximproxetil für die Identifizierung von Unreinheit H, European Pharmacopoeia (EP) Reference Standard